Radcliffe & CardioNerds @AHA22: PROGRESSIVE-AF: Impact of “First-Line” Rhythm Therapy on Afib Progression

• Arrhythmia AcademyinnovationsRadcliffe & CardioNerds @AHA22: PROGRESSIVE-AF: Impact of “First-Line” Rhythm Therapy on Afib Progression

• Jason Andrade, Kate Wilcox
• 15.11.22
• 

  permission request

  ×

  First Name*

  Last Name*

  Institution/Company*

  Email Address*

  Job Title*

  Telephone Number*

  Content reuse purpose*

  Circulation *

AHA 22 – Dr Kate Wilcox, CardioNerds Academic Fellow (Medical College of Wisconsin, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Jason Andrade (Vancouver General/Montreal Heart Institute, CA), investigator of the late-breaking PROGRESSIVE-AF trial (NCT05514860).

The aim of PROGRESSIVE-AF is to assess if the initial treatment choice, cryoballoon-based PVI or anti-arrhythmic drug therapy influences AF disease progression, as measured by continuous cardiac monitoring.

The trial showed that first-line ablation was associated with a significantly lower progression to persistent atrial fibrillation when compared to initial anti-arrhythmic drug therapy.

Access our full AHA 22 Scientific Coverage here.

Recorded remotely from Montreal and Wisconsin.

Editor: Mirjam Boros
Video Specialist: Oliver Miles